[exclusive] Jiangsu Pharmaceutical Research Institute ~ overview of drug research and development in recent years!

Jiangsu, a big pharmaceutical Province, is located in the first-class Pharmaceutical University in China There are many first-class pharmaceutical enterprises in China There are a group of top pharmaceutical talents living here Because of this, when we talk about the development of pharmacy in Jiangsu Province, the key words such as "Pharma", "Hengrui", "Tianqing", "hausen" appear on the paper Here, we seem to forget an old state-owned pharmaceutical research institute, which is the leading role today - Jiangsu pharmaceutical research Institute! 1 Company profile Jiangsu Institute of medicine, formerly the Institute of medicine of Nanjing Institute of Pharmacy (China University of Pharmaceutical Sciences), became an independent Institute of medicine of Nanjing in July 1962, affiliated to the Department of health of Jiangsu Province, and later renamed Jiangsu Institute of medicine; in December 2006, the Institute of medicine was transferred to Nanjing University of technology as a whole, which is a state-owned scientific research institution specialized in new drug innovation and development and research Preclinical research base   Jiangsu Pharmaceutical Research Institute has complete discipline construction and scientific research equipment, including Jiangsu drug safety evaluation center (National GLP certification), Jiangsu new drug preparation research and Engineering Technology Service Center, Jiangsu experimental animal quality testing station (national metrology certification) and other platforms, with pharmaceutical chemistry research room, natural drug research room, pharmacology and toxicology research room, pharmaceutical preparations and Quality research office, drug packaging material compatibility research center, medical device compatibility research and testing center have formed a complete pre clinical research technology system for new drugs At present, the Institute has 94 employees, 73 scientific researchers, 6 senior professional titles, 15 deputy senior executives, 6 doctors, 25 masters, 2 provincial "333" talent projects, and 4 provincial top six talent peaks 2 The achievements obtained by Jiangsu Pharmaceutical Research Institute have certain ability of new drug research and development, and have made good achievements in the research and development of new drug products A total of 139 national new drug certificates have been obtained, and the conversion rate of new drug achievements has reached over 98% Antimony 273, a sustained-release preparation for the treatment of schistosomiasis, was the first sustained-release formulation in the Pharmacopoeia of China in the 1970s Amphotericin B liposome for injection and paclitaxel liposome for injection became the first liposome formulation listed in China In addition to the above achievements, in recent years, the Institute has undertaken 2 National 863 projects, 12 National Natural Science Foundation projects, 5 national key projects, 8 national new drug fund projects, 2 World Bank loans, 53 provincial and ministerial level key projects, 10 international cooperation projects, 42 department and bureau level projects, and more than 700 domestic horizontal cooperation projects Among them, more than 50 research achievements have won awards (1 International Award, National It has won 34 invention patents, 5 level awards, 26 ministerial and provincial awards, published more than 800 papers in various academic journals at home and abroad, compiled and participated in the compilation of more than 20 monographs and translations, conducted academic exchanges with the United States, Britain, France, Japan, Germany, Sweden, Belgium, Australia, Southeast Asia and other countries in international exchanges, received nearly 50 groups of more than 100 experts to visit the Institute, and visited the world The World Health Organization (who), the international organization for the development of Chemical Sciences (iocd), the Institute of Ophthalmology and pharmacology of Texas A & M University, the United States, the boshlan company of the United States and Hong Kong Fugao Pharmaceutical Co., Ltd have established scientific research cooperation relations, 25 people have participated in international academic exchanges, and 3 experts have served as members or directors of international professional institutions 3 Representative transformation achievements 1) paclitaxel liposome for injection has become the first liposome dosage form to be listed at home and abroad, which has transferred green leaf Cisco Pharmaceutical (Kanghai pharmaceutical) with a production value of 1.2 billion yuan / year and won the first prize of China Pharmaceutical Association (2012) and the second prize of Jiangsu Province Science and technology progress (2010) 2) Amphotericin B liposome for injection is the first new drug in China, and its achievements have been successfully transferred to Shanghai New pioneer Pharmaceutical Co., Ltd., with an output value of 1.2 billion yuan / year 4 the registration of drugs was inquired through the drug intelligence data After 2000, the number of drug applications of Jiangsu drug research institute was 114 (111 independent products) 79 drugs have been approved, one is under review, and the approval rate is 83%; for the trend of drug declaration, since 2000, the most years of declaration are 2002, a total of 33; the most years of approval are 2001 and 2002, both of which are 21; from 2000 to 2005, the number of drug declarations in six years is 109, a total of 78; after 2006, both the number of declaration and the number of approval , both of which are relatively low, and the trend is shown in the following figure: Figure 3: after 2000, the drug trend declared by Jiangsu Institute of drugs (drug intelligence data) For the specific dosage forms of the declared specific drugs, most of the dosage forms of Jiangsu Institute of pharmaceutical research are involved After 2000, the most involved drugs are tablets (27 pieces), injections (19 pieces) and powder injections (15 pieces) See the following figure for details: Figure 4: distribution of dosage forms involved in the declared drugs of Jiangsu Institute of pharmaceutical research (intelligence data) In the field of treatment, Jiangsu Pharmaceutical Research Institute has a relatively wide range of research fields After 2000, in terms of drug declaration, the top three declaration quantity are digestive tract and metabolism (28 pieces), systemic anti infective drugs (18 pieces), nervous system (15 pieces); the number and percentage of declaration in related fields are as follows: Figure 5: treatment fields and percentages (intelligence data) of the drugs declared by Jiangsu Institute of medicine 5 In recent years, class 2 and class 3 chemical drugs declared by Jiangsu Institute of Medicine Through drug intelligence data query, in recent years, the chemical drugs declared by Jiangsu Institute of medicine mainly focus on Category 2 and Category 3, while the declaration of traditional Chinese medicine only has a few varieties The following table shows the details of category 2 and Category 3 chemical drugs declared by Jiangsu Institute of medicine since 2000: table 1: after 2000, category 2 and Category 3 chemical drugs declared by Jiangsu Institute of medicine 6 Patent application Through the search of patent retrieval system on the official website of the State Intellectual Property Office, 21 pieces of data information (application date 1988-1996) were input by the applicant of the search project into Nanjing Pharmaceutical Research Institute, while 41 pieces of data information (application date 1998-present) were displayed by the search of Jiangsu Pharmaceutical Research Institute; the number of applications in the past 10 years totaled 10, and the number of open applications totaled 19; and the number of open applications totaled 19; and According to a search, the top three patent applications in recent years are su Guoqiang (13), Lu Bushi (10) and Wei Yingjie (10) 7 Small insights: From the perspective of origin, the discipline accumulation and cultural heritage of Nanjing Pharmaceutical College is undoubted; from the perspective of region, deep in the pharmaceutical Province, the impetus of technology development wave is also strong; however, compared with many state-owned research institutes and institutes of the same level in China, its competitiveness is not only in terms of staffing, discipline construction, but also in terms of scientific research achievements transformation and output All of them are deficient, which seems to be somewhat inconsistent with their origins and regions Of course, from the perspective of an "outsider", we still need to know what the research institute with such a long history has gone through in these years that is not known by the outside world, so it is wrong to simply evaluate it unilaterally from its official information Anyway, I hope that in the future, with the help of the existing technology platform, the Institute will not forget its original intention, continue to move forward and show its unique glory! Reference: 1 Pharmaceutical intelligence data 2 Official website of Jiangsu Pharmaceutical Research Institute 3 Official website of State Intellectual Property Office